Relevance of aspirin (acetylsalicylic acid) in the prevention of cardiovascular events

Authors

Abstract

Relevance of aspirin (acetylsalicylic acid) in the prevention of cardiovascular events

Downloads

Download data is not yet available.

References

1. Gaziano JM, Brotons C, Coppolecchia R, Cricelli C, Darius H, Gorelick PB, et al. Use of aspirin to reduce risk of initial vascular events in patients at moderate risk of cardiovascular disease (ARRIVE): a randomised, double-blind, placebo-controlled trial. Lancet. 2018;392(10152):1036-46. DOI: https://doi.org/10.1016/s0140-6736(18)31924-x

2. Mahmoud AN, Gad MM, Elgendy AY, Elgendy IY, Bavry AA. Efficacy and safety of aspirin for primary prevention of cardiovascular events: a meta-analysis and trial sequential analysis of randomized controlled trials. Eur Heart J. 2019;40(7):607-17. DOI: https://doi.org/10.1093/eurheartj/ehy813

3. Castilla-Guerra L, Fernández-Moreno MDC, de la Vega-Sánchez JM, León Jiménez D. Evaluación del riesgo hemorrágico de la terapia antitrombótica en pacientes con ictus. Clin Investig Arterioscler. 2019;31(6):282-8. DOI: https://doi.org/10.1016/j.arteri.2019.01.006

4. Steering Committee of the Physicians' Health Study Research Group. Final report on the aspirin component of the ongoing Physicians' Health Study. N Engl J Med. 1989;321(3):129-35. DOI: https://doi.org/10.1056/nejm198907203210301

5. Hennekens CH, Dalen JE. Aspirin in the treatment and prevention of cardiovascular disease: past and current perspectives and future directions. Am J Med. 2013;126(5):373-8. DOI: https://doi.org/10.1016/j.amjmed.2012.12.013

Downloads

Published

2021-04-18

How to Cite

1.
Díaz-Rodríguez YL. Relevance of aspirin (acetylsalicylic acid) in the prevention of cardiovascular events. CorSalud [Internet]. 2021 Apr. 18 [cited 2025 Jun. 23];13(2):256-7. Available from: https://revcorsalud.sld.cu/index.php/cors/article/view/626

Issue

Vol. 13 No. 2 (2021)

Section

LETTERS TO THE EDITOR

License

Authors who publish with this journal agree to the following terms:

    1. Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
    2. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.